PK/PD Modeling of a Novel Pleuromutilin Derivative Pleuro2-4 against Mycoplasma gallisepticum in Chicks.

Authors

Feifei Zhao, Yizhen Zhu, Tingting Zhang, Wei Wei, Honghao Huang, Dongping Zeng, Wenguang Xiong, Youzhi Tang, Zhenling Zeng

Published in

Journal of agricultural and food chemistry. Volume 74. Issue 41. Pages 32357-32367. Oct 21, 2026.

Abstract

Mycoplasma gallisepticum is a major causative agent of chronic respiratory disease in poultry, and effective antimicrobial therapy remains essential for disease control. In this study, the antimycoplasmal activity, pharmacokinetics, therapeutic efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) model of Pleuro2-4, a novel pleuromutilin candidate, were systematically evaluated against M. gallisepticum. Pleuro2-4 exhibited potent in vitro activity (MIC = 0.0078 μg/mL) and concentration-dependent killing. Following oral administration in chicks, Pleuro2-4 was rapidly converted to its active metabolite and displayed rapid absorption and sustained exposure in lung tissue. In an M. gallisepticum infection model, Pleuro2-4 alleviated respiratory lesions, reduced mycoplasmal loads, and suppressed inflammatory responses. PK/PD integration using an inhibitory sigmoid Emax model identified AUC0-24h/MIC as the PK/PD index for dose optimization. The bactericidal target was 3372.82 h, corresponding to a recommended oral dosage of 44.99 mg/kg once daily for three consecutive days. These findings support Pleuro2-4 as a promising candidate for avian mycoplasmosis treatment.

PMID:
42904995
Bibliographic data and abstract were imported from PubMed on 23 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.